Table 2.

PD-related characteristics and measures of the patient sample.

Disease duration (years)	Hoehn and Yahr	UPDRS-III (medical OFF)	UPDRS-III (medical ON)	MDRS (medical ON)	MoCA* (medical ON)	LED [mg]	Motor subtype (AR | TD | MT)	Symptom lateralization (right | left)
8.9 (±5.7) [0–21]	2.6 (±0.7) [1–4]	35.2 (±11.5) [15–57]	21.1 (±10.9) [6–47]	137.1 (±6.4) [118–144]	24.5 (±3.7) [16–29]	1023.0 (±435.0) [100–1,900]	13 | 5 | 21 (33% | 13% | 54%)	16 | 23 (41% | 59%)

Values for disease duration, Hoehn and Yahr stage, UPDRS-III, MDRS and LED are mean (±standard deviation) [value range]. UPDRS-III, Unified Parkinson's Disease Rating Scale part III; MDRS, Mattis Dementia Rating Scale. MoCA, Montreal Cognitive Assesment (

^*MoCA was available in 33 of 39 patients). LED, Levodopa equivalent dose; AR, akinetic-rigid; TD, tremor-dominant; MT, mixed type.